By Brazil Stock Guide – Amil led the monthly ranking of net beneficiary additions among Brazil’s major health plan operators in March, in a sign of relief for a sector that remains under pressure from churn, medical inflation and tougher pricing dynamics.
Data from ANS, Brazil’s private health regulator, compiled by BTG Pactual, show that the healthcare industry added about 79,000 lives in March after a weak start to the year. Even so, the sector still ended the first quarter with a net loss of roughly 32,000 beneficiaries. In other words, March looked better than the quarter — but not enough to call it a broad-based recovery.
A Selective Rebound
BTG described the March figures as a “strong March print” and a “good print for the HC industry,” with Amil and Bradsaúde standing out. But the data point to a differentiated market rather than a rising tide for all operators. Some companies regained scale in key regions, while others continued to lose members or struggled to defend their portfolios.
The clearest message is competitive rotation. Operators with stronger distribution, relevant corporate exposure and better ability to retain members in profitable markets gained ground. Those with higher churn, weaker retention or more limited pricing power remained under pressure.
Amil at the Top
Amil added 34,936 lives in March, the strongest monthly performance among the large operators tracked by BTG. The gain was driven mainly by São Paulo and Rio de Janeiro, two of Brazil’s most important health plan markets because of their concentration of corporate clients, higher average tickets and dense hospital networks.
For international readers, the point is not only that Amil gained members. It is that it gained them in the markets that matter most. After years of operational adjustments, the company appears to be rebuilding commercial momentum. In the first quarter, Amil added around 66,000 lives, making it one of the clearest winners in the period.
Bradsaúde’s Quarter
Bradsaúde, the new brand associated with the former Bradesco Saúde, ranked second in March, with 26,939 net additions. But it was the strongest performer for the full quarter, adding about 86,000 lives among large operators.
That matters because the Bradsaúde story is broader than one month of growth. The platform combines a large corporate client base, bank distribution, brand recognition and potential integration with a wider healthcare ecosystem. BTG said it sees Bradsaúde as an “attractive entry point” into a “scalable healthcare platform,” with re-rating potential as hospital assets mature, capital allocation improves and new growth initiatives advance.
Network and Scale
SulAmérica, part of the Rede D’Or (RDOR3) ecosystem, ranked third in March, with 25,453 lives added. The operator gained around 17,000 beneficiaries in the first quarter. The reading is positive, but it needs qualification: in healthcare, growth only creates value if the new lives come with adequate pricing, manageable claims and a good regional mix.
That is why SulAmérica’s growth in São Paulo and Rio de Janeiro matters. These are the markets where network quality, pricing power and hospital integration can have a more direct impact on profitability. BTG also said Rede D’Or remains its top pick in the sector, citing consistent execution in both hospitals and insurance, improving profitability, the Bradesco joint venture and potential M&A opportunities.
Hapvida’s Mixed Signal
Hapvida (HAPV3) ranked fourth in March, with 21,739 lives added. The monthly number was relevant because it marked a recovery, especially in Rio de Janeiro. But the investment reading remains more ambiguous: Hapvida still lost about 35,000 lives in the first quarter.
That is particularly important for Hapvida because its model relies heavily on scale, vertical integration and occupancy across its own healthcare network. Gaining lives in Rio helps, but continued losses in São Paulo and Pernambuco limit the positive interpretation. March reduced the pressure, but it did not yet confirm an operational turnaround.
The Weak End
After the four main winners, the ranking showed smaller gains for Unimed Seguros, with 7,675 lives, Prevent Senior, with 741, and Athena, with 612. The negative side started with Omint, which lost 1,302 lives, followed by Central Unimed, down 14,667, Porto Saúde, down 17,856, and Assim, down 20,374.
Porto Saúde deserves attention because it had been seen as a growth platform in Brazilian healthcare. Its loss of nearly 18,000 lives in March and a slightly negative quarter suggest that portfolio expansion has become harder in a market where price increases, client retention and claims control now matter more than raw growth.
What the Ranking Does Not Show
A ranking of lives is useful, but it should not be read as automatic proof of better operating performance. In health plans, adding members can be good or bad depending on the portfolio mix. A company can grow by adding lower-ticket lives, higher-risk contracts or members with worse claims behavior. It can also lose unprofitable lives and improve margins.
That is why the correct reading of March is cautious. The sector showed signs of recomposition, but the quality of that growth still needs to be tested in earnings. The next indicators to watch are average ticket, corporate renewals, claims ratio, churn, delinquency and medical margin.
Leave a Reply